http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103755707-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5517 |
| filingDate | 2013-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103755707-B |
| titleOfInvention | Lixivaptan crystal form II and its production and use |
| abstract | The invention belongs to heart failure resistance pharmaceutical field, more particularly, relate to crystal form II of lixivaptan (lixivaptan) and preparation method thereof, containing its pharmaceutical composition and the purposes in manufacture treatment hyponatremia medicine thereof.Lixivaptan crystal form II of the present invention is with the chloro-4-nitrobenzoic acid of 2-for starting raw material, and through esterification, hydro-reduction, acylations, hydrolysis, the reactions steps such as chloride obtain.The lixivaptan purity obtained is 97.5%.This lixivaptan crystal form II characterizes with its powder x-ray diffraction figure.In view of good development prospect and the pharmacy value of this compound, obtain purity high, have and determine crystal formation very much and the compound of favorable reproducibility is important. |
| priorityDate | 2013-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 117.